DEA Advances Psilocybin Rescheduling Petition to HHS for Scientific Review
The DEA's decision to forward psilocybin rescheduling for scientific review marks a significant regulatory shift that could expand medical access for veterans and palliative care patients while accelerating psychedelic research.
